Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

F Song; R Fux; LB Provacia; A Volz; M Eickmann; S Becker; Ab Osterhaus; Bart Haagmans; G Sutter

doi:10.1128/JVI.01672-13

Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

F Song, R Fux, LB Provacia, A Volz, M Eickmann, S Becker, Ab Osterhaus, Bart Haagmans, G Sutter

Virology

Research output: Contribution to journal › Article › Academic › peer-review

117 Citations (Scopus)

Abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.

Original language	Undefined/Unknown
Pages (from-to)	11950-11954
Number of pages	5
Journal	Journal of Virology
Volume	87
Issue number	21
DOIs	https://doi.org/10.1128/JVI.01672-13
Publication status	Published - 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1128/JVI.01672-13

http://hdl.handle.net/1765/68656

Cite this

@article{e80a26dd419f4885b3b81a3418098079,

title = "Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies",

abstract = "Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.",

author = "F Song and R Fux and LB Provacia and A Volz and M Eickmann and S Becker and Ab Osterhaus and Bart Haagmans and G Sutter",

year = "2013",

doi = "10.1128/JVI.01672-13",

language = "Undefined/Unknown",

volume = "87",

pages = "11950--11954",

journal = "Journal of Virology",

issn = "0022-538X",

publisher = "American Society for Microbiology",

number = "21",

}

TY - JOUR

T1 - Middle East Respiratory Syndrome Coronavirus Spike Protein Delivered by Modified Vaccinia Virus Ankara Efficiently Induces Virus-Neutralizing Antibodies

AU - Song, F

AU - Fux, R

AU - Provacia, LB

AU - Volz, A

AU - Eickmann, M

AU - Becker, S

AU - Osterhaus, Ab

AU - Haagmans, Bart

AU - Sutter, G

PY - 2013

Y1 - 2013

N2 - Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.

AB - Middle East respiratory syndrome coronavirus (MERS-CoV) has recently emerged as a causative agent of severe respiratory disease in humans. Here, we constructed recombinant modified vaccinia virus Ankara (MVA) expressing full-length MERS-CoV spike (S) protein (MVA-MERS-S). The genetic stability and growth characteristics of MVA-MERS-S make it a suitable candidate vaccine for clinical testing. Vaccinated mice produced high levels of serum antibodies neutralizing MERS-CoV. Thus, MVA-MERS-S may serve for further development of an emergency vaccine against MERS-CoV.

U2 - 10.1128/JVI.01672-13

DO - 10.1128/JVI.01672-13

M3 - Article

SN - 0022-538X

VL - 87

SP - 11950

EP - 11954

JO - Journal of Virology

JF - Journal of Virology

IS - 21

ER -